The Ministry of Health of the Russian Federation has registered "Phenylephrine, 2.5% Eye Drops" manufactured by the FSUE Moscow Endocrine Plant, the marketing authorisation No. LP-006921, the registration date is 09.04.2021.
"Phenylephrine, 2.5% Eye Drops" (INN phenylephrine) belongs to the pharmacotherapeutic group of α-adrenergic agonists.
When applied topically in ophthalmology the medicine causes pupil dilation, improves the outflow of intraocular fluid and narrows the vessels of a conjunctiva. Phenylephrine has an expressed stimulating effect on postsynaptic α-adrenergic receptors, has a very weak effect on β-adrenergic receptors of the heart. The medicine has a vasoconstrictor effect similar to that of norepinephrine (noradrenaline), while it has practically no chronotropic and ionotropic effects on the heart. The vasopressor effect of phenylephrine is weaker than that of norepinephrine, but is more prolonged. It causes vasoconstriction 30-90 seconds after instillation, the duration is 2-6 hours. After instillation phenylephrine contracts a pupil dilator and smooth muscles of arterioles of a conjunctiva, thereby causing a pupil dilation. Mydriasis occurs within 10-60 minutes after a single instillation of 2.5% phenylephrine solution and persists for 2 hours. Mydriasis caused by phenylephrine is not accompanied by cycloplegia.
"Phenylephrine, 2.5% Eye Drops" can be used for the following indications:
- iridocyclitis (to prevent the occurrence of posterior synechiae and reduce exudation from an iris);
- for diagnostic pupil dilation during ophthalmoscopy and other procedures necessary to monitor the condition of the posterior segment of an eye;
- conducting of a provocative test in patients with a narrow angle of an anterior chamber of an eye and suspected angle-closure glaucoma;
- differential diagnosis of superficial and deep injection of an eyeball;
- syndrome of "red eye" (to reduce hyperemia and irritability of a mucous membrane of an eye);
- accommodation spasm (in adults and children from 6 years old).
The introduction into civil circulation of the first commercial series of the drug "Phenylephrine, 2.5% Eye Drops” produced by the FSUE Moscow Endocrine Plant, is planned in May 2021.
The FSUE Moscow Endocrine Plant Started the Production of «Phenylephrine 2.5% Eye Drops»
26 May 2021
Comment type is not specified in the component properties.